Need to keep on high of the science and politics driving biotech at the moment? Enroll to get our biotech e-newsletter in your inbox.
Morning. At the moment, we check out the dramatic finances cuts on the NIH proposed by the Trump administration, see how high authorities well being officers seem like taking a softer line than some anticipated on gene therapies, and extra.
The necessity-to-know this morning
- Merck mentioned its experimental, oral PCSK9 inhibitor lowered ranges of unhealthy ldl cholesterol in individuals with genetically excessive ldl cholesterol, attaining the objectives of two Section 3 research. No information had been reported in its press launch. Merck is conducting a big, cardiovascular outomes research.
- Keros Therapeutics mentioned it would return $375 million in “extra capital” to shareholders. The choice was made on the finish of a strategic evaluate of its operations, and notably, after Adar1 Capital Administration, a biotech hedge fund and Keros’ largest shareholder, accused administration of losing cash.
- Avidity Biosciences mentioned it obtained clearance from the FDA to hunt accelerated approval for an RNA-based drug to deal with facioscapulohumeral muscular dystrophy (FSHD). Individually, the corporate reported new research outcomes displaying its drug, known as del-brax, improved perform in sufferers with FSHD.
- Axsome Therapeutics mentioned the FDA issued a “refuse to file” letter, turning again its software looking for the approval of a remedy for fibromyalgia.
- Struggling “zombie” biotech Elevation Oncology is being acquired by Concentra Biosciences and will probably be shut down.
Metsera’s amylin drug reveals early potential
Metsera, the obesity-focused biotech, mentioned this morning that its drug candidate focusing on the amylin hormone confirmed marked efficacy in an early trial and the potential to have longer-lasting results than present weight reduction therapies available on the market which are injected weekly.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
